Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Cash from Operations of 136400000.0 for Q2 2026, up 33.73% year-over-year from 102000000.0 in Q2 2025, and down 6.45% on a QoQ basis from 145800000.0 in Q1 2026.
Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Cash from Operations for 17 years, with the latest figure at 136400000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 136400000.0, up 33.73% year-over-year; the trailing twelve-month figure through Jun 2026 was 898100000.0 (up 58.31% YoY), and the FY2025 annual result was 782700000.0, up 31.46% from the prior year.
- Cash from Operations declined to 136400000.0 in Q2 2026, from 145800000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 388400000.0 in Q4 2025 and troughed at 125200000.0 in Q1 2023.
- A 5-year average of 132755555.56 and a median of 137250000.0 in 2022 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2022, when Cash from Operations soared 3304.76%; it then tumbled 209.14% in 2023.
- A 5-year view of Cash from Operations shows it stood at 143000000.0 in 2022, then decreased by 13.64% to 123500000.0 in 2023, then surged by 96.36% to 242500000.0 in 2024, then jumped by 60.16% to 388400000.0 in 2025, then plunged by 64.88% to 136400000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 136400000.0 in Q2 2026, 145800000.0 in Q1 2026, and 388400000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 145.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136.40 Mn |
| Jun 30, 2026 | 136.40 Mn |
| Mar 31, 2026 | 145.80 Mn |
| Mar 31, 2026 | 145.80 Mn |
| Dec 31, 2025 | 388.40 Mn |
| Dec 31, 2025 | 388.40 Mn |
| Sep 30, 2025 | 227.50 Mn |
| Sep 30, 2025 | 227.50 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Mar 31, 2025 | 64.80 Mn |
| Mar 31, 2025 | 64.80 Mn |
| Dec 31, 2024 | 242.50 Mn |
| Dec 31, 2024 | 242.50 Mn |
| Sep 30, 2024 | 158.00 Mn |
| Sep 30, 2024 | 158.00 Mn |
| Jun 30, 2024 | 64.60 Mn |
| Jun 30, 2024 | 64.60 Mn |
| Mar 31, 2024 | 130.30 Mn |
| Mar 31, 2024 | 130.30 Mn |